Matthew R. Cooperberg, MD, MPH

Dr. Cooperberg

Matthew R. Cooperberg, MD, MPH

Professor of Urology; Epidemiology & Biostatistics
Helen Diller Family Chair in Urology
Associate Chair, Research
Chief of Urology, San Francisco VAMC
Co-Leader, Prostate Program, HDFCCC


BA, 1995, English, Dartmouth College, Hanover, NH
MPH, 2000, Yale University School of Epidemiology and Public Health, New Haven, CT
MD, 2000, Medicine, Yale University School of Medicine, New Haven, CT


Matthew Cooperberg, MD, MPH received his undergraduate training from Dartmouth College, where he earned a degree in English with high honors. He then enrolled in Yale University's MD, MPH program, concurrently earning an MPH with a concentration in Health Policy from the School of Epidemiology and Public Health, and a MD from the School of Medicine. He completed his General Surgery and Urology training at the University of California, San Francisco, and subsequently continued at UCSF to complete a fellowship in Urologic Oncology under the guidance of Peter Carroll, MD, MPH. In 2009, Dr. Cooperberg was recruited to join the faculty at UCSF and the San Francisco Veterans Affairs Medical Center. Specializing in urologic cancer care, he is part of the multidisciplinary urologic oncology team of the UCSF Helen Diller Family Comprehensive Cancer Center, located primarily at the Mission Bay campus. He also maintains privileges at San Francisco General Hospital. In 2013, Cooperberg received the first Helen Diller Family Chair in Urology and a secondary appointment in the Department of Epidemiology and Biostatistics. In 2015 he won the American Urological Association Gold Cystoscope Award, given annually to one urologist for contributions to the field in the first 10 years of practice, and was also named Young Urologist of the Year. He was named professor in 2018.

Clinical Interests

Dr. Cooperberg's clinical interests include the early detection, diagnosis, and management of genitourinary malignancy, and using minimally invasive techniques to treat benign and malignant diseases. He performs robotic, laparoscopic, endoscopic, and percutaneous surgeries, and is interested in incorporating promising new technologies into his practice. He is particularly interested in risk-stratifying prostate, renal, and other tumors, and matching treatments appropriately to those patients most likely to benefit, using novel imaging tests and biomarkers together with clinical information. Dr. Cooperberg is a Fellow of the American College of Surgeons, and a member of the American Urological Association (AUA) and the Society for Urologic Oncology. In 2012. Dr. Cooperberg co-wrote a proposal to establish a national urology registry. From this proposal developed the AUA Quality (AQUA) Registry, a national database tracking practice patterns, quality of care, and both clinical and patient-reported outcomes for patients across the U.S. with prostate cancer and other urologic conditions. Dr. Cooperberg continues in a senior leadership role with the project.

Research Interests

Drawing on the CaPSURE registry, UCSF’s institutional databases, and other data resources, Dr. Cooperberg has written over 295 peer-reviewed scientific articles, and has been invited to present his research findings at many national and international conferences. His primary research focus is prostate cancer, with particular areas of interest including: 1) health services research, documenting ongoing trends and regional variation in the use of diagnostic, imaging, and therapeutic interventions for men with all stages of prostate cancer; 2) risk assessment and biomarker research, developing and validating prognostic tools incorporating both standard clinical information and emerging biomarkers; 3) comparative effectiveness research, examining evidence regarding the relative benefits of surgery, radiation, and other treatments in terms of cancer control, quality of life, and cost; and 4) decision support and survivorship, helping men make better-informed decisions about both treatments and management of short- and long-term treatment sequelae. He is also very interested in disparities in prostate cancer access and outcomes, and in prostate cancer as an international disease. He helped forge a number of inter-continental collaborations which are yielding fascinating insights into prostate cancer’s variation in presentation and outcome around the world. He has received numerous awards for his research papers and is co-investigator on multiple grants. He won a prestigious Young Investigator Award from the Prostate Cancer Foundation, and is a current investigator on a number of ongoing Federal grants including his first R01 as principle investigator, awarded in 2016 to study microRNAs as candidate prostate cancer biomarkers.



This series of videos, Dr. Matt Cooperberg provides an overview of clinically localized prostate cancer, intended primarily for newly diagnosed patients and their families, covering risk stratification, active surveillance, surgery (prostatectomy), radiation therapy, and focal therapy.

Patient Contact

Note that UCSF Urology utilizes an online system for scheduling appointments called MyChart. This is our preferred method of communications. If you are not yet signed up for MyChart, call 415.514.6000 to get an activation code and help signing up.
For new patients click here and follow instructions under "Urologic Surgical Oncology" 

For existing patients, general questions and making follow up appointment:

415.514.2720  (Phone)
415.353.9785 (Fax)

1825 4th Street
6th floor Baker Precision Cancer Medicine Building
San Francisco, CA 94158

Practice Manager
415.514.8825  (Phone)
415.353.7093  (Fax)


Academic Contact

415.885.3660  (Phone)
415.476.5366  (Fax)

University of California, San Francisco
Department of Urology, Mailcode 1695
550 16th Street, 6th Floor
San Francisco, CA 94143

Follow Me on Twitter